In this episode of the BeeWellWithMS podcast, hosted by Dr. Agne Straukiene, an MS neurologist, key insights and reflections from the ECTRIMS 2024 conference in Copenhagen are shared. The event, featuring over 8,000 attendees, spotlighted emerging MS treatments, including high-dose vitamin D3, BTK inhibitor from the Hercules and Gemini two trials, and the updated McDonald criteria for MS diagnosis. Various interviews with MS experts and MS patients provide further discussion on topics such as MS fatigue, MS sleep disorders, cognitive function in MS, and the potential role of digital technology in MS treatment and holistic patient care. Despite some disappointing findings regarding statins for MS progression, the conference emphasized the importance of ongoing MS research, early MS diagnosis, and new approaches to measuring success in MS treatments.Become a supporter of this podcast: https://www.spreaker.com/podcast/beewellwithms-podcast-by-dr-agne-straukiene--5762905/support.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related